Abstract
Patients with intermediate or high-grade non-Hodgkin's lymphoma are rarely cured of their disease after the failure of conventional therapy. Autologous bone marrow transplantation (ABMT) offers such patients a new possibility of cure. Our purpose was to evaluate the usefulness of radiotherapy in these patients who did not achieve complete remission of disease after high-dose chemotherapy (HDCT) followed by ABMT or who had previous bulky disease. In this study we examined 10 patients: after HDCT + ABMT, 9 patients had persistent disease and 1 patient with previous bulky disease was in complete remission. All patients underwent involved-field radiotherapy administered by a 6-18 MV linear accelerator, total mean dose 4000 cGy (range, 3200-5000 cGy). At the end of radiotherapy we observed 6 complete responses and 4 progressions of disease outside the radiotherapy field. No serious side effects were observed. To date, of the 6 complete responses 2 have relapsed (after 9 and 11 months) and 4 are alive and disease free at 24 months (range, 8-39 months) after radiotherapy. In our opinion, radiotherapy is an effective treatment after HDCT + ABMT and may have a role in a prospective multidisciplinary approach.
| Original language | English |
|---|---|
| Pages (from-to) | 335-338 |
| Number of pages | 4 |
| Journal | Tumori |
| Volume | 82 |
| Issue number | 4 |
| Publication status | Published - Jul 1996 |
Fingerprint
Keywords
- autologous bone marrow transplantation
- non-Hodgkin's lymphoma
- radiotherapy
ASJC Scopus subject areas
- Cancer Research
Cite this
Radiotherapy after high-dose chemotherapy followed by autologous bone marrow transplantation in patients with intermediate or high-grade non-Hodgkin's lymphoma. / Barra, Salvina; Bacigalupo, Almalina; Corvò, Renzo; Guenzi, Marina; Scolaro, Tindaro; Vitale, Vito.
In: Tumori, Vol. 82, No. 4, 07.1996, p. 335-338.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Radiotherapy after high-dose chemotherapy followed by autologous bone marrow transplantation in patients with intermediate or high-grade non-Hodgkin's lymphoma
AU - Barra, Salvina
AU - Bacigalupo, Almalina
AU - Corvò, Renzo
AU - Guenzi, Marina
AU - Scolaro, Tindaro
AU - Vitale, Vito
PY - 1996/7
Y1 - 1996/7
N2 - Patients with intermediate or high-grade non-Hodgkin's lymphoma are rarely cured of their disease after the failure of conventional therapy. Autologous bone marrow transplantation (ABMT) offers such patients a new possibility of cure. Our purpose was to evaluate the usefulness of radiotherapy in these patients who did not achieve complete remission of disease after high-dose chemotherapy (HDCT) followed by ABMT or who had previous bulky disease. In this study we examined 10 patients: after HDCT + ABMT, 9 patients had persistent disease and 1 patient with previous bulky disease was in complete remission. All patients underwent involved-field radiotherapy administered by a 6-18 MV linear accelerator, total mean dose 4000 cGy (range, 3200-5000 cGy). At the end of radiotherapy we observed 6 complete responses and 4 progressions of disease outside the radiotherapy field. No serious side effects were observed. To date, of the 6 complete responses 2 have relapsed (after 9 and 11 months) and 4 are alive and disease free at 24 months (range, 8-39 months) after radiotherapy. In our opinion, radiotherapy is an effective treatment after HDCT + ABMT and may have a role in a prospective multidisciplinary approach.
AB - Patients with intermediate or high-grade non-Hodgkin's lymphoma are rarely cured of their disease after the failure of conventional therapy. Autologous bone marrow transplantation (ABMT) offers such patients a new possibility of cure. Our purpose was to evaluate the usefulness of radiotherapy in these patients who did not achieve complete remission of disease after high-dose chemotherapy (HDCT) followed by ABMT or who had previous bulky disease. In this study we examined 10 patients: after HDCT + ABMT, 9 patients had persistent disease and 1 patient with previous bulky disease was in complete remission. All patients underwent involved-field radiotherapy administered by a 6-18 MV linear accelerator, total mean dose 4000 cGy (range, 3200-5000 cGy). At the end of radiotherapy we observed 6 complete responses and 4 progressions of disease outside the radiotherapy field. No serious side effects were observed. To date, of the 6 complete responses 2 have relapsed (after 9 and 11 months) and 4 are alive and disease free at 24 months (range, 8-39 months) after radiotherapy. In our opinion, radiotherapy is an effective treatment after HDCT + ABMT and may have a role in a prospective multidisciplinary approach.
KW - autologous bone marrow transplantation
KW - non-Hodgkin's lymphoma
KW - radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=0029803228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029803228&partnerID=8YFLogxK
M3 - Article
VL - 82
SP - 335
EP - 338
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 4
ER -